WeVote
Log In

Bill

Bill

HB 772

AN ACT relating to pharmaceutical manufacturers.

2025 Regular Session

HB 772 addresses pharmaceutical manufacturer policies in Kentucky, though specific provisions remain unclear pending committee review and bill text release.

to Health Services (H)
#drugsandmedicines #pharmacists #publichealth
0
WeVote Research Nonpartisan
Bill Summary · HB 772

Legislative bill overview

HB 772 is a Kentucky House bill relating to pharmaceutical manufacturers that was recently introduced and referred to the Health Services Committee. Without access to the bill's specific text, language, or stated provisions, the precise nature of proposed regulations, incentives, or requirements cannot be determined at this stage.

Why is this important

Pharmaceutical manufacturing policy affects drug pricing, availability, local economic development, and healthcare access for Kentucky residents. Such legislation can influence whether manufacturers establish or expand operations in-state, which has implications for jobs, tax revenue, and drug supply chains.

Potential points of contention

  • Drug pricing mechanisms – Whether the bill addresses affordability, cost transparency, or profit margins may draw opposition from manufacturers concerned about market competitiveness versus advocates demanding lower costs
  • Regulatory burden vs. incentives – Disagreement likely over whether new compliance requirements or reporting mandates create excessive burdens on smaller manufacturers
  • State vs. federal authority – Questions about whether Kentucky regulations conflict with or duplicate federal FDA oversight and interstate commerce considerations

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.